{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:03:08Z","timestamp":1762452188653,"version":"build-2065373602"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Russian state","award":["#121112900214-2","#121112900214-2"],"award-info":[{"award-number":["#121112900214-2","#121112900214-2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10822-025-00654-9","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:16:44Z","timestamp":1757917004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospects for the structure\u2012function evolution of SARS-CoV-2 main protease inhibitors"],"prefix":"10.1007","volume":"39","author":[{"given":"Anatoliy A.","family":"Bulygin","sequence":"first","affiliation":[]},{"given":"Nikita A.","family":"Kuznetsov","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"654_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong E, Du H, Gardner L (2020) An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 20:533\u2013534. https:\/\/doi.org\/10.1016\/S1473-3099(20)30120-1","journal-title":"Lancet Infect Dis"},{"key":"654_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa2001017","journal-title":"N Engl J Med"},{"key":"654_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3233\/HAB-200420","volume":"29","author":"AA Gebru","year":"2021","unstructured":"Gebru AA, Birhanu T, Wendimu E, Ayalew AF, Mulat S, Abasimel HZ, Kazemi A, Tadesse BA, Gebru BA, Deriba BS et al (2021) Global burden of COVID-19: situational analyis and review. Hum Antibodies 29:139\u2013148. https:\/\/doi.org\/10.3233\/HAB-200420","journal-title":"Hum Antibodies"},{"key":"654_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1021\/acs.jproteome.0c00808","volume":"20","author":"S Tushir","year":"2021","unstructured":"Tushir S, Kamanna S, Nath SS, Bhat A, Rose S, Aithal AR, Tatu U (2021) Proteo-Genomic analysis of SARS-CoV-2: a clinical landscape of single-nucleotide polymorphisms, COVID-19 proteome, and host responses. J Proteome Res 20:1591\u20131601. https:\/\/doi.org\/10.1021\/acs.jproteome.0c00808","journal-title":"J Proteome Res"},{"key":"654_CR5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/cbic.202000047","volume":"21","author":"JS Morse","year":"2020","unstructured":"Morse JS, Lalonde T, Xu S, Liu WR (2020) Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem 21:730\u2013738. https:\/\/doi.org\/10.1002\/cbic.202000047","journal-title":"ChemBioChem"},{"key":"654_CR6","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","volume":"60","author":"D Siegel","year":"2017","unstructured":"Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, Carra E, Lew W, Ross B et al (2017) Discovery and synthesis of a phosphoramidate prodrug of a Pyrrolo[2,1- f ][Triazin-4-Amino] adenine C -Nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem 60:1648\u20131661. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01594","journal-title":"J Med Chem"},{"key":"654_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","volume":"6","author":"RM Cox","year":"2021","unstructured":"Cox RM, Wolf JD, Plemper RK (2021) Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol 6:11\u201318. https:\/\/doi.org\/10.1038\/s41564-020-00835-2","journal-title":"Nat Microbiol"},{"key":"654_CR8","doi-asserted-by":"publisher","unstructured":"Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Sch\u00e4fer A, Dinnon KH, Stevens LJ et al (2020) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 12. https:\/\/doi.org\/10.1126\/scitranslmed.abb5883","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"654_CR9","doi-asserted-by":"publisher","first-page":"eabe0751","DOI":"10.1126\/sciadv.abe0751","volume":"6","author":"MD Sacco","year":"2020","unstructured":"Sacco MD, Ma C, Lagarias P, Gao A, Townsend JA, Meng X, Dube P, Zhang X, Hu Y, Kitamura N et al (2020) Structure and Inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M pro and cathepsin L. Sci Adv 6:eabe0751. https:\/\/doi.org\/10.1126\/sciadv.abe0751","journal-title":"Sci Adv"},{"key":"654_CR10","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ et al (2021) An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science 374:1586\u20131593. https:\/\/doi.org\/10.1126\/science.abl4784","journal-title":"Science"},{"key":"654_CR11","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1126\/science.abf1611","volume":"371","author":"J Qiao","year":"2021","unstructured":"Qiao J, Li Y-S, Zeng R, Liu F-L, Luo R-H, Huang C, Wang Y-F, Zhang J, Quan B, Shen C et al (2021) SARS-CoV-2 M pro inhibitors with antiviral activity in a Transgenic mouse model. Science 371:1374\u20131378. https:\/\/doi.org\/10.1126\/science.abf1611","journal-title":"Science"},{"key":"654_CR12","doi-asserted-by":"publisher","unstructured":"de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O\u2019Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A et al (2021) A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL pro inhibitor PF-00835231 as a potential new treatment for COVID-19. J Virol 95. https:\/\/doi.org\/10.1128\/JVI.01819-20","DOI":"10.1128\/JVI.01819-20"},{"key":"654_CR13","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","volume":"30","author":"C Ma","year":"2020","unstructured":"Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, Zhang X, Tarbet B, Marty MT, Chen Y, Boceprevir et al (2020) GC-376, and Calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res 30:678\u2013692. https:\/\/doi.org\/10.1038\/s41422-020-0356-z","journal-title":"Cell Res"},{"key":"654_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1021\/acsptsci.1c00099","volume":"4","author":"Z Xia","year":"2021","unstructured":"Xia Z, Sacco M, Hu Y, Ma C, Meng X, Zhang F, Szeto T, Xiang Y, Chen Y, Wang J (2021) Rational design of hybrid SARS-CoV-2 main protease inhibitors guided by the superimposed cocrystal structures with the peptidomimetic inhibitors GC-376, telaprevir, and boceprevir. ACS Pharmacol Transl Sci 4:1408\u20131421. https:\/\/doi.org\/10.1021\/acsptsci.1c00099","journal-title":"ACS Pharmacol Transl Sci"},{"key":"654_CR15","doi-asserted-by":"publisher","first-page":"114596","DOI":"10.1016\/j.ejmech.2022.114596","volume":"240","author":"YR Alugubelli","year":"2022","unstructured":"Alugubelli YR, Geng ZZ, Yang KS, Shaabani N, Khatua K, Ma XR, Vatansever EC, Cho C-C, Ma Y, Xiao J et al (2022) A systematic exploration of Boceprevir-Based main protease inhibitors as SARS-CoV-2 antivirals. Eur J Med Chem 240:114596. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114596","journal-title":"Eur J Med Chem"},{"key":"654_CR16","doi-asserted-by":"publisher","first-page":"6463","DOI":"10.1038\/s41467-023-42102-y","volume":"14","author":"X Jiang","year":"2023","unstructured":"Jiang X, Su H, Shang W, Zhou F, Zhang Y, Zhao W, Zhang Q, Xie H, Jiang L, Nie T et al (2023) Structure-Based development and preclinical evaluation of the SARS-CoV-2 3\u00a0C-like protease inhibitor Simnotrelvir. Nat Commun 14:6463. https:\/\/doi.org\/10.1038\/s41467-023-42102-y","journal-title":"Nat Commun"},{"key":"654_CR17","doi-asserted-by":"publisher","unstructured":"Chen X, Huang X, Ma Q, Kuzmi\u010d P, Zhou B, Xu J, Liu B, Jiang H, Zhang W, Yang C et al (2023) Inhibition mechanism and antiviral activity of an \u03b1-Ketoamide based SARS-CoV-2 main protease inhibitor. bioRxiv 629249. https:\/\/doi.org\/10.1101\/2023.03.09.531862","DOI":"10.1101\/2023.03.09.531862"},{"key":"654_CR18","doi-asserted-by":"publisher","first-page":"eadi0979","DOI":"10.1126\/scitranslmed.adi0979","volume":"16","author":"M Westberg","year":"2024","unstructured":"Westberg M, Su Y, Zou X, Huang P, Rustagi A, Garhyan J, Patel PB, Fernandez D, Wu Y, Hao C et al (2024) An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Sci Transl Med 16:eadi0979. https:\/\/doi.org\/10.1126\/scitranslmed.adi0979","journal-title":"Sci Transl Med"},{"key":"654_CR19","doi-asserted-by":"publisher","first-page":"13550","DOI":"10.1021\/acs.jmedchem.3c02469","volume":"67","author":"CMN Allerton","year":"2024","unstructured":"Allerton CMN, Arcari JT, Aschenbrenner LM, Avery M, Bechle BM, Behzadi MA, Boras B, Buzon LM, Cardin RD, Catlin NR et al (2024) A second-generation oral SARS-CoV-2 main protease inhibitor clinical candidate for the treatment of COVID-19. J Med Chem 67:13550\u201313571. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c02469","journal-title":"J Med Chem"},{"key":"654_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1021\/acsmedchemlett.2c00030","volume":"13","author":"CSB Chia","year":"2022","unstructured":"Chia CSB (2022) Novel nitrile peptidomimetics for treating COVID-19. ACS Med Chem Lett 13:330\u2013331. https:\/\/doi.org\/10.1021\/acsmedchemlett.2c00030","journal-title":"ACS Med Chem Lett"},{"key":"654_CR21","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1021\/acsinfecdis.0c00815","volume":"7","author":"K Steuten","year":"2021","unstructured":"Steuten K, Kim H, Widen JC, Babin BM, Onguka O, Lovell S, Bolgi O, Cerikan B, Neufeldt CJ, Cortese M et al (2021) Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19. ACS Infect Dis 7:1457\u20131468. https:\/\/doi.org\/10.1021\/acsinfecdis.0c00815","journal-title":"ACS Infect Dis"},{"key":"654_CR22","doi-asserted-by":"publisher","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","volume":"63","author":"RL Hoffman","year":"2020","unstructured":"Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, He M, Hogan RJ, Kozminski K, Li LY et al (2020) Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J Med Chem 63:12725\u201312747. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01063","journal-title":"J Med Chem"},{"key":"654_CR23","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/s41467-022-29915-z","volume":"13","author":"DW Kneller","year":"2022","unstructured":"Kneller DW, Li H, Phillips G, Weiss KL, Zhang Q, Arnould MA, Jonsson CB, Surendranathan S, Parvathareddy J, Blakeley MP et al (2022) Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease. Nat Commun 13:2268. https:\/\/doi.org\/10.1038\/s41467-022-29915-z","journal-title":"Nat Commun"},{"key":"654_CR24","first-page":"2535","volume":"10","author":"Y-C Wang","year":"2020","unstructured":"Wang Y-C, Yang W-H, Yang C-S, Hou M-H, Tsai C-L, Chou Y-Z, Hung M-C, Chen Y (2020) Structural basis of SARS-CoV-2 main protease Inhibition by a Broad-Spectrum Anti-Coronaviral drug. Am J Cancer Reslind 10:2535\u20132545","journal-title":"Am J Cancer Reslind"},{"key":"654_CR25","doi-asserted-by":"publisher","unstructured":"Yang KS, Ma XR, Ma Y, Alugubelli YR, Scott DA, Vatansever EC, Drelich AK, Sankaran B, Geng ZZ, Blankenship LR et al (2021) A quick route to multiple highly potent SARS-CoV\u20102 main protease inhibitors**. ChemMedChem  16, 942\u2013948. https:\/\/doi.org\/10.1002\/cmdc.202000924","DOI":"10.1002\/cmdc.202000924"},{"key":"654_CR26","doi-asserted-by":"publisher","unstructured":"Andi B, Kumaran D, Kreitler DF, Soares AS, Keereetaweep J, Jakoncic J, Lazo EO, Shi W, Fuchs MR, Sweet RM et al (2022) Hepatitis C virus NS3\/4A inhibitors and other Drug-like compounds as covalent binders of SARS-CoV-2 main protease. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-022-15930-z","DOI":"10.1038\/s41598-022-15930-z"},{"key":"654_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham MJ, Murtola T, Schulz R, P\u00e1ll S, Smith JC, Hess B, Lindah E (2015) Gromacs: high performance molecular simulations through Multi-Level parallelism from laptops to supercomputers. SoftwareX 1\u20132:19\u201325. https:\/\/doi.org\/10.1016\/j.softx.2015.06.001","journal-title":"SoftwareX"},{"key":"654_CR28","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/prot.22711","volume":"78","author":"K Lindorff-Larsen","year":"2010","unstructured":"Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, Shaw DE (2010) Improved side-chain torsion potentials for the amber ff99SB protein force field. Proteins 78:1950\u20131958. https:\/\/doi.org\/10.1002\/prot.22711","journal-title":"Proteins"},{"key":"654_CR29","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/j.cpc.2013.06.003","volume":"184","author":"S P\u00e1ll","year":"2013","unstructured":"P\u00e1ll S, Hess BA (2013) Flexible algorithm for calculating pair interactions on SIMD architectures. Comput Phys Commun 184:2641\u20132650. https:\/\/doi.org\/10.1016\/j.cpc.2013.06.003","journal-title":"Comput Phys Commun"},{"key":"654_CR30","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/ci500020m","volume":"54","author":"R Kumari","year":"2014","unstructured":"Kumari R, Kumar R, Lynn A (2014) G_mmpbsa\u2014a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 54:1951\u20131962. https:\/\/doi.org\/10.1021\/ci500020m","journal-title":"J Chem Inf Model"},{"key":"654_CR31","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete VSADME (2017) A free web tool to evaluate pharmacokinetics, drug-Likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"},{"key":"654_CR32","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/ci200387c","volume":"52","author":"J Ali","year":"2012","unstructured":"Ali J, Camilleri P, Brown MB, Hutt AJ, Kirton SB (2012) Revisiting the general solubility equation: In Silico prediction of aqueous solubility incorporating the effect of topographical Polar surface area. J Chem Inf Model 52:420\u2013428. https:\/\/doi.org\/10.1021\/ci200387c","journal-title":"J Chem Inf Model"},{"key":"654_CR33","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1021\/ci034243x","volume":"44","author":"JS Delaney","year":"2004","unstructured":"Delaney JS (2004) ESOL: estimating aqueous solubility directly from molecular structure. J Chem Inf Comput Sci 44:1000\u20131005. https:\/\/doi.org\/10.1021\/ci034243x","journal-title":"J Chem Inf Comput Sci"},{"key":"654_CR34","doi-asserted-by":"publisher","unstructured":"Daina A, Zoete VA, BOILED-Egg To (2016) Predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 11, 1117\u20131121. https:\/\/doi.org\/10.1002\/cmdc.201600182","DOI":"10.1002\/cmdc.201600182"},{"key":"654_CR35","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1021\/jm000942e","volume":"43","author":"P Ertl","year":"2000","unstructured":"Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular Polar surface area as a sum of Fragment-Based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714\u20133717. https:\/\/doi.org\/10.1021\/jm000942e","journal-title":"J Med Chem"},{"key":"654_CR36","doi-asserted-by":"publisher","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of Original Article: S0169-409X(96)00423-1. The article was originally published in advanced drug delivery reviews. Adv Drug Deliv Rev 46:3\u201326 (2001). https:\/\/doi.org\/10.1016\/S0169-409X(00)00129-0","DOI":"10.1016\/S0169-409X(00)00129-0"},{"key":"654_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1021\/cc9800071","volume":"1","author":"AK Ghose","year":"1999","unstructured":"Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1:55\u201368. https:\/\/doi.org\/10.1021\/cc9800071","journal-title":"J Comb Chem"},{"key":"654_CR38","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"DF Veber","year":"2002","unstructured":"Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615\u20132623. https:\/\/doi.org\/10.1021\/jm020017n","journal-title":"J Med Chem"},{"key":"654_CR39","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1021\/jm000292e","volume":"43","author":"WJ Egan","year":"2000","unstructured":"Egan WJ, Merz KM, Baldwin JJ (2000) Prediction of drug absorption using multivariate statistics. J Med Chem 43:3867\u20133877. https:\/\/doi.org\/10.1021\/jm000292e","journal-title":"J Med Chem"},{"key":"654_CR40","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1021\/jm015507e","volume":"44","author":"I Muegge","year":"2001","unstructured":"Muegge I, Heald SL, Brittelli D (2001) Simple selection criteria for drug-like chemical matter. J Med Chem 44:1841\u20131846. https:\/\/doi.org\/10.1021\/jm015507e","journal-title":"J Med Chem"},{"key":"654_CR41","doi-asserted-by":"publisher","first-page":"W513","DOI":"10.1093\/nar\/gkae303","volume":"52","author":"P Banerjee","year":"2024","unstructured":"Banerjee P, Kemmler E, Dunkel M, Preissner R (2024) ProTox 3.0: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 52:W513\u2013W520. https:\/\/doi.org\/10.1093\/nar\/gkae303","journal-title":"Nucleic Acids Res"},{"key":"654_CR42","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ejmech.2013.05.005","volume":"65","author":"P Thanigaimalai","year":"2013","unstructured":"Thanigaimalai P, Konno S, Yamamoto T, Koiwai Y, Taguchi A, Takayama K, Yakushiji F, Akaji K, Kiso Y, Kawasaki Y et al (2013) Design, synthesis, and biological evaluation of novel Dipeptide-Type SARS-CoV 3CL protease inhibitors: structure\u2013activity relationship study. Eur J Med Chem 65:436\u2013447. https:\/\/doi.org\/10.1016\/j.ejmech.2013.05.005","journal-title":"Eur J Med Chem"},{"key":"654_CR43","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1021\/jm0603926","volume":"49","author":"S Yang","year":"2006","unstructured":"Yang S, Chen S-J, Hsu M-F, Wu J-D, Tseng C-TK, Liu Y-F, Chen H-C, Kuo C-W, Wu C-S, Chang L-W et al (2006) Synthesis, crystal structure, structure\u2009\u2014activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J Med Chem 49:4971\u20134980. https:\/\/doi.org\/10.1021\/jm0603926","journal-title":"J Med Chem"},{"key":"654_CR44","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1016\/j.bmc.2005.05.065","volume":"13","author":"J-J Shie","year":"2005","unstructured":"Shie J-J, Fang J-M, Kuo T-H, Kuo C-J, Liang P-H, Huang H-J, Wu Y-T, Jan J-T, Cheng Y-SE, Wong C-H (2005) Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic \u03b1,\u03b2-Unsaturated esters. Bioorg Med Chem 13:5240\u20135252. https:\/\/doi.org\/10.1016\/j.bmc.2005.05.065","journal-title":"Bioorg Med Chem"},{"key":"654_CR45","doi-asserted-by":"publisher","first-page":"7962","DOI":"10.1021\/jm200870n","volume":"54","author":"K Akaji","year":"2011","unstructured":"Akaji K, Konno H, Mitsui H, Teruya K, Shimamoto Y, Hattori Y, Ozaki T, Kusunoki M, Sanjoh A (2011) Structure-based design, synthesis, and evaluation of Peptide-Mimetic SARS 3CL protease inhibitors. J Med Chem 54:7962\u20137973. https:\/\/doi.org\/10.1021\/jm200870n","journal-title":"J Med Chem"},{"key":"654_CR46","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41401-020-0483-6","volume":"41","author":"H Su","year":"2020","unstructured":"Su H, Yao S, Zhao W, Li M, Liu J, Shang W, Xie H, Ke C, Hu H, Gao M et al (2020) Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 41:1167\u20131177. https:\/\/doi.org\/10.1038\/s41401-020-0483-6","journal-title":"Acta Pharmacol Sin"},{"key":"654_CR47","doi-asserted-by":"publisher","first-page":"113584","DOI":"10.1016\/j.ejmech.2021.113584","volume":"222","author":"W Vuong","year":"2021","unstructured":"Vuong W, Fischer C, Khan MB, van Belkum MJ, Lamer T, Willoughby KD, Lu J, Arutyunova E, Joyce MA, Saffran HA et al (2021) Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: structural enhancements, increased solubility, and micellar studies. Eur J Med Chem 222:113584. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113584","journal-title":"Eur J Med Chem"},{"key":"654_CR48","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-Ketoamide inhibitors. Science 368:409\u2013412. https:\/\/doi.org\/10.1126\/science.abb3405","journal-title":"Science"},{"key":"654_CR49","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.bbrc.2021.03.096","volume":"555","author":"K Vandyck","year":"2021","unstructured":"Vandyck K, Abdelnabi R, Gupta K, Jochmans D, Jekle A, Deval J, Misner D, Bardiot D, Foo CS, Liu C et al (2021) ALG-097111, a potent and selective SARS-CoV-2 3-Chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian hamster model. Biochem Biophys Res Commun 555:134\u2013139. https:\/\/doi.org\/10.1016\/j.bbrc.2021.03.096","journal-title":"Biochem Biophys Res Commun"},{"key":"654_CR50","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/s41467-022-29413-2","volume":"13","author":"H Liu","year":"2022","unstructured":"Liu H, Iketani S, Zask A, Khanizeman N, Bednarova E, Forouhar F, Fowler B, Hong SJ, Mohri H, Nair MS et al (2022) Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun 13:1891. https:\/\/doi.org\/10.1038\/s41467-022-29413-2","journal-title":"Nat Commun"},{"key":"654_CR51","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.bmc.2012.11.017","volume":"21","author":"S Konno","year":"2013","unstructured":"Konno S, Thanigaimalai P, Yamamoto T, Nakada K, Kakiuchi R, Takayama K, Yamazaki Y, Yakushiji F, Akaji K, Kiso Y et al (2013) Design and synthesis of new Tripeptide-Type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety. Bioorg Med Chem 21:412\u2013424. https:\/\/doi.org\/10.1016\/j.bmc.2012.11.017","journal-title":"Bioorg Med Chem"},{"key":"654_CR52","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/v17040491","volume":"17","author":"C Delgado","year":"2025","unstructured":"Delgado C, Nogara PA, Miranda MD, Rosa AS, Ferreira VNS, Batista LT, Oliveira TKF, Omage FB, Motta F, Bastos IM et al (2025) In silico and in vitro studies of the approved antibiotic Ceftaroline fosamil and its metabolites as inhibitors of SARS-CoV-2 replication. Viruses 17:491. https:\/\/doi.org\/10.3390\/v17040491","journal-title":"Viruses"},{"key":"654_CR53","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/v15071480","volume":"15","author":"S Zabo","year":"2023","unstructured":"Zabo S, Lobb KA (2023) In silico substrate-binding profiling for SARS-CoV-2 main protease (Mpro) using hexapeptide substrates. Viruses 15:1480. https:\/\/doi.org\/10.3390\/v15071480","journal-title":"Viruses"},{"key":"654_CR54","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1080\/14756366.2021.1954919","volume":"36","author":"M Pavan","year":"2021","unstructured":"Pavan M, Bolcato G, Bassani D, Sturlese M, Moro S (2021) Supervised molecular dynamics (SuMD) insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. J Enzyme Inhib Med Chem 36:1645\u20131649. https:\/\/doi.org\/10.1080\/14756366.2021.1954919","journal-title":"J Enzyme Inhib Med Chem"},{"key":"654_CR55","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1021\/acscatal.0c05522","volume":"11","author":"CA Ramos-Guzm\u00e1n","year":"2021","unstructured":"Ramos-Guzm\u00e1n CA, Ruiz-Pern\u00eda JJ, Tu\u00f1\u00f3n I (2021) Multiscale simulations of SARS-CoV-2 3CL protease Inhibition with aldehyde derivatives. Role of protein and inhibitor conformational changes in the reaction mechanism. ACS Catal 11:4157\u20134168. https:\/\/doi.org\/10.1021\/acscatal.0c05522","journal-title":"ACS Catal"},{"key":"654_CR56","doi-asserted-by":"publisher","first-page":"25933","DOI":"10.1002\/anie.202110027","volume":"60","author":"CA Ramos-Guzm\u00e1n","year":"2021","unstructured":"Ramos-Guzm\u00e1n CA, Ruiz\u2010Pern\u00eda JJ, Tu\u00f1\u00f3n I (2021) Inhibition mechanism of SARS\u2010CoV\u20102 main protease with ketone\u2010based inhibitors unveiled by multiscale simulations: insights for improved designs**. Angew Chem Intl Edit 60:25933\u201325941. https:\/\/doi.org\/10.1002\/anie.202110027","journal-title":"Angewandte Chemie Intl Edit"},{"key":"654_CR57","doi-asserted-by":"publisher","first-page":"104886","DOI":"10.1016\/j.jbc.2023.104886","volume":"299","author":"A Kovalevsky","year":"2023","unstructured":"Kovalevsky A, Aniana A, Coates L, Bonnesen PV, Nashed NT, Louis JM (2023) Contribution of the catalytic dyad of SARS-CoV-2 main protease to binding covalent and noncovalent inhibitors. J Biol Chem 299:104886. https:\/\/doi.org\/10.1016\/j.jbc.2023.104886","journal-title":"J Biol Chem"},{"key":"654_CR58","doi-asserted-by":"publisher","unstructured":"AbouYoussef ML, Aboelnga MM, Hanafy NA, El-Kelany KE (2025) K36-Based inhibitor analogs as potential therapeutics against SARS-CoV-2 main protease (Mpro): a computational investigation. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-025-06676-5","DOI":"10.1038\/s41598-025-06676-5"},{"key":"654_CR59","doi-asserted-by":"publisher","first-page":"12347","DOI":"10.1080\/07391102.2021.1970626","volume":"40","author":"GM Ferreira","year":"2022","unstructured":"Ferreira GM, Kronenberger T, Tonduru AK, Hirata RDC, Hirata MH, Poso A (2022) SARS-COV-2 Mpro conformational changes induced by covalently bound ligands. J Biomol Struct Dyn 40:12347\u201312357. https:\/\/doi.org\/10.1080\/07391102.2021.1970626","journal-title":"J Biomol Struct Dynamics"},{"key":"654_CR60","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1016\/j.bmcl.2016.05.036","volume":"26","author":"P Li","year":"2016","unstructured":"Li P, Yang B, Hao F, Wang P, He H, Huang L, Zhang X, Zhang S, Peng X, Yin K et al (2016) Design, synthesis, and biological evaluation of Anti-EV71 agents. Bioorg Med Chem 26:3346\u20133350. https:\/\/doi.org\/10.1016\/j.bmcl.2016.05.036","journal-title":"Bioorg Med Chem"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00654-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-025-00654-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00654-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:56:54Z","timestamp":1762451814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-025-00654-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["654"],"URL":"https:\/\/doi.org\/10.1007\/s10822-025-00654-9","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"type":"print","value":"0920-654X"},{"type":"electronic","value":"1573-4951"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human and animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}],"article-number":"78"}}